Effect of Angiotensin-Neprilysin Inhibition (ARNI) on Prognosis of Chronic Heart Failure
Status:
Recruiting
Trial end date:
2022-01-31
Target enrollment:
Participant gender:
Summary
This study is a randomized controlled multicenter clinical trial, in which about 340 patients
with newly diagnosed or prior diagnosed chronic heart will be recruited. Patients will be
randomly divided into Angiotensin-Neprilysin Inhibition (ARNI) group and
angiotensin-converting enzyme inhibitors or angiotensin receptor blockers (ACEI/ARB) group.
All-cause death, cardiac death and re-hospitalization due to heart failure will be evaluated
in 1, 3, 6, 12 months after recruitment.
Phase:
N/A
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University
Collaborators:
Baoji Central Hospital First Affiliated Hospital Xi'an Medical University First Hospital of Xi'an
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination